Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18063508 | 0.89 | LMNA (0.53) | BPTFHTR2AROCK2CCNE1CDK2 | |
| SCHEMBL18153340 | 0.84 | ROCK2 (0.65) | BPTFROCK2CCNE1CDK2ROCK1 | |
| SCHEMBL23221453 | 0.81 | BPTF (0.54) | BPTFHTR2AROCK2CCNE1CDK2 | |
| SCHEMBL20042148 | 0.81 | BPTF (0.51) | BPTFHTR2AROCK2CCNE1CDK2 | |
| SCHEMBL21015069 | 0.80 | GALR2 (0.43) | HTR2ACCNE1CDK2HTR2CKMT2A | |
| SCHEMBL20042176 | 0.80 | ROCK2 (0.67) | BPTFROCK2CCNE1CDK2ROCK1 | |
| SCHEMBL18153408 | 0.80 | BPTF (0.52) | BPTFHTR2AROCK2CCNE1CDK2 | |
| SCHEMBL18087205 | 0.78 | PKM (0.53) | CCNE1CDK2KMT2AMEN1MAPT | |
| SCHEMBL20042167 | 0.78 | BPTF (0.53) | BPTFHTR2AROCK2CCNE1CDK2 | |
| SCHEMBL20042174 | 0.77 | POLB (0.60) | BPTFROCK2CCNE1CDK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057592-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3057592-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10220034-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220034-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | BPTF 2828/4885HTR2A 4517/4885ROCK2 2833/4885 |
| US-10220034-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | BPTF 2828/4885HTR2A 4517/4885ROCK2 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.